export const COPY = {
  banner: {
    eyebrow: 'Rx Only',
    frame1Headline: 'Cryo-ready. Wake clear.',
    frame1Sub: 'Stellaria™ (morphanidine-C) 12 mg tablets',
    frame2Headline: 'Zero post-thaw hangover in clinical trials.',
    frame2Sub: 'For licensed deep-space crew prescribed pre-mission.',
    frame3Stat: '412',
    frame3StatLabel: 'Pilots studied',
    frame3Headline: 'Cleared for missions ≥ 2.4 AU.',
    frame3Sub: 'Studied across Mars-transit and Belt-rotation protocols.',
    cta: 'Learn More',
    isiTitle: 'Important Safety Information',
  },

  email: {
    subject: 'Stellaria™: cryo-induction support for long-haul crew',
    preheader:
      'Indicated for hibernation-assist on missions ≥90 days. Please see full prescribing information.',
    heroEyebrow: 'Now available for Fleet Medical formularies',
    heroHeadline: 'Clarity on arrival.',
    heroBody:
      'Stellaria™ (morphanidine-C) is a prescription hibernation-assist tablet indicated for cryo-induction support in licensed deep-space personnel on missions of 90 days or longer. In the pivotal ORION-3 trial, pilots administered Stellaria prior to cryosleep reported a 94% reduction in post-thaw cognitive fog versus placebo at T+0:30.',
    cta: 'Learn More',
    benefits: [
      {
        label: '01 / Homeostatic support',
        title: 'Stabilizes core functions through induction.',
        body: 'Supports cardiovascular, metabolic, and neural homeostasis across the induction-to-thaw window without sustained sedative load.',
      },
      {
        label: '02 / Wake clarity',
        title: 'Eliminates post-thaw cognitive fog.',
        body: 'In controlled trials, 94% of subjects achieved full psychomotor baseline within 30 minutes of re-animation (vs. 12% on placebo).',
      },
      {
        label: '03 / Fleet-tested',
        title: 'Cleared for missions ≥90 days.',
        body: 'Studied across 412 pilots on Mars-transit and Belt-rotation protocols. Compatible with standard Class-II cryo berths.',
      },
    ],
    references: [
      '1. Okafor RN, Tanaka H, et al. ORION-3: A Phase III trial of morphanidine-C in cryo-induction support. J Interstellar Med. 2094;41(3):218–230.',
      '2. Deep Space Pharma. STELLARIA (morphanidine-C) tablets prescribing information. Luna Prime, DSP; 2095.',
      '3. Fleet Medical Advisory 24-MC-07. Standards for pharmacologic cryo-induction support. UNSA Medical Command; 2094.',
    ],
    footerAddress: 'Deep Space Pharma, Tower 4, Shackleton Medical Park, Luna Prime 00471.',
    footerUnsub:
      'You received this because you are a licensed healthcare provider on the DSP Fleet Medical list. Unsubscribe or update preferences.',
    footerLegal:
      '© 2095 Deep Space Pharma. STELLARIA and the DSP travel mark are trademarks of Deep Space Pharma. STL-PI-2095-03.',
  },

  isi: {
    boxedWarning: {
      title: 'WARNING: ION DRIVE CO-EXPOSURE AND CARDIAC ARRHYTHMIA',
      body: 'Concurrent ion drive co-exposure within 6 hours of Stellaria administration has been associated with prolonged QT interval and, in rare cases, Torsades-class arrhythmia during cryo-induction. Do not administer Stellaria within 6 hours of active ion drive proximity (≤40 m, shielded), or within 12 hours (unshielded). Obtain a baseline ECG prior to first dose and prior to any subsequent cryo-induction cycle.',
    },
    sections: [
      {
        heading: 'Indication',
        body: 'STELLARIA (morphanidine-C) tablets are indicated as hibernation-assist therapy in licensed deep-space personnel ≥21 years of age undergoing planned cryo-induction on missions of 90 days or longer. Stellaria is intended for pre-mission administration under the supervision of a Fleet Medical Officer.',
      },
      {
        heading: 'Contraindications',
        body: 'Stellaria is contraindicated in patients with: known hypersensitivity to morphanidine-C or any tablet excipient; active cryo-sensitization syndrome (CSS); uncorrected Grade II or higher telomeric instability; concurrent use of Class-III temporal stabilizers (e.g., chronazepam, temporalin); pregnancy confirmed or suspected at time of dosing.',
      },
      {
        heading: 'Warnings and Precautions',
        body: 'Cardiac effects: see Boxed Warning. Hypothalamic set-point drift has been reported during first-exposure inductions; monitor core temperature for 90 minutes post-thaw. Neuro-vestibular effects, including transient orientation loss, may occur on re-animation; patients should not perform EVA duties for 120 minutes post-thaw.',
      },
      {
        heading: 'Adverse Reactions',
        body: 'Most common adverse reactions (≥5%, vs. placebo) in the ORION-3 trial were: dry mouth (11%), mild paresthesia of the extremities during re-animation (9%), transient temporal displacement (7%), metallic taste (6%), and mild photosensitivity for up to 24 hours post-thaw (5%).',
      },
      {
        heading: 'Drug Interactions',
        body: 'Avoid concurrent use with Class-III temporal stabilizers and with monoamine oxidase inhibitors within 14 days. Ion drive co-exposure: see Boxed Warning. Caffeine analogs (>400 mg/day caf-eq) may blunt induction onset; advise patients to discontinue 48 hours prior to dosing.',
      },
      {
        heading: 'Use in Specific Populations',
        body: 'Pregnancy: contraindicated; morphanidine-C crosses the placental barrier with unknown effects on fetal cryo-tolerance. Lactation: not recommended. Pediatric use: safety and effectiveness not established in patients under 21 years. Hepatic/renal impairment: reduce dose by 50% in moderate impairment; contraindicated in severe.',
      },
      {
        heading: 'Please see full Prescribing Information, including Boxed Warning, at stellaria-hcp.dsp.',
        body: '',
        isFooter: true,
      },
    ],
  },
} as const;
